Although most study - authors were positive , we could not draw firm conclusions about any of the pharmaceutical interventions .
Even patients that received placebo intervention showed improvement .
There is weak evidence that reduction mammaplasty may be helpful to treat inframammary intertrigo .
Conclusions There is no evidence at all about the prevention of intertrigo and there is no firm evidence about its treatment .
Background Intertrigo in the large skin folds is a common problem .
There is a plethora of treatments , but a lack of evidence about their efficacy .
A nursing guideline on this matter had to be up date d and broadened in scope to other health care professionals .
A comparison of the efficacy of oral fluconazole, 150 mg/week versus 50 mg/day, in the treatment of tinea corporis, tinea cruris, tinea pedis, and cutaneous candidosis.
Two hundred and forty five patients with dermatophytoses and cutaneous c and idosis were enrolled in the study ; 122 were r and omized to the once-weekly regimen and 123 to the once-daily regimen . Subjects included both men and women ; the average age was 42 years . There were no statistically significant differences between the two groups with regard to age , sex , race , and body weight distributions . In the group receiving once-weekly fluconazole , there were 58 tinea pedis infections and 77 nonpedis infections ( tinea corporis , tinea cruris , and cutaneous c and idosis ) . In the group receiving once-daily fluconazole , there were 56 tinea pedis infections and 76 nonpedis infections . The duration of infection and total score of signs and symptoms did not differ significantly between the two groups . Patients received treatment until clinical ly cured or up to a maximum of 6 weeks for tinea pedis and 4 weeks for tinea corporis , tinea cruris , or cutaneous c and idosis . Medical history , physical and laboratory examinations , and the clinical diagnosis were recorded . Clinical and mycologic examinations and laboratory testing were performed at baseline and 2 weeks after treatment initiation , and then weekly until clinical ly cured or the maximum duration of treatment allowed was reached . Safety analysis was performed for all patients . Follow-up clinical and mycologic examinations were performed 1 month after the therapy ended . The clinical efficacy was based on cure ( disappearance of all baseline signs and symptoms of infection ) , marked improvement , moderate improvement , failure ( no change or worsening of the signs and symptoms ) , or unevaluable ( most commonly due to protocol evaluations or the absence of an identified pathogen ) . Mycologic efficacy was based on eradication ( absence of pathogen on microscopy and /or culture ) , persistence ( presence of pathogen on microscopy and /or culture ) , superinfection ( absence of pathogen , but with a different fungal pathogen on microscopy and culture associated with clinical disease ) , or unevaluable . Long-term follow-up evaluation included the category relapse , defined as the absence of pathogen at the end of treatment , with the reappearance of that pathogen on microscopy and /or culture at follow-up visit . The culture result determined the efficacy where discrepancies between microscopy and culture findings occurred
Although most study - authors were positive , we could not draw firm conclusions about any of the pharmaceutical interventions .
Even patients that received placebo intervention showed improvement .
There is weak evidence that reduction mammaplasty may be helpful to treat inframammary intertrigo .
Conclusions There is no evidence at all about the prevention of intertrigo and there is no firm evidence about its treatment .
Background Intertrigo in the large skin folds is a common problem .
There is a plethora of treatments , but a lack of evidence about their efficacy .
A nursing guideline on this matter had to be up date d and broadened in scope to other health care professionals .